Animal models of multiple sclerosis-Potentials and limitations

Progress in Neurobiology

Volumn 92, Issue 3, 2010, Pages 386-404

  Mix, Eilhard ^a   Meyer Rienecker, Hans ^a   Hartung, Hans Peter ^b   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Animal model; Autoimmunity; Experimental autoimmune encephalomyelitis; Immunogenetics; Immunomodulatory therapy; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; CD3 ANTIBODY; CD4 ANTIBODY; CEFTRIAXONE; CLADRIBINE; CYCLOSPORIN A; CYTOKINE; DACLIZUMAB; ERYTHROPOIETIN; FINGOLIMOD; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; PENTOXIFYLLINE; PHENYTOIN; RITUXIMAB; ROLIPRAM; ROQUINIMEX; SALAZOSULFAPYRIDINE; TEMSIROLIMUS; TERIFLUNOMIDE; TGN 1412; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE STORM; DEMYELINATION; DRUG FEVER; DRUG MECHANISM; GENE EXPRESSION; GENE THERAPY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENETICS; INJECTION SITE REACTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; MYALGIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; REGULATORY T LYMPHOCYTE; REVIEW; SCREENING; SIDE EFFECT; STEM CELL TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TH3 CELL; TRANSGENICS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION PROFILING; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS;

EID: 77956080330     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2010.06.005     Document Type: Review

References (358)

1. Afzali B., Lombardi G., Lechler R.I., Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 2007, 148:32-46.
2. Agnello D., Bigini P., Villa P., Mennini T., Cerami A., Brines M.L., Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002, 952:128-134.
3. Aharoni R., Teitelbaum D., Sela M., Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10821-10826.
4. Aharoni R., Herschkovitz A., Eilam R., Blumberg-Hazan M., Sela M., Brück W., Arnon R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11358-11363.
5. Aharonowiz M., Einstein O., Fainstein N., Lassmann H., Reubinoff B., Ben-Hur T. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS One 2008, 3:e3145. (1-10).
6. Aktas O., Waiczies S., Smorodchenko A., Dorr J., Seeger B., Prozorovski T., Sallach S., Endres M., Brocke S., Nitsch R., Zipp F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 2003, 197:725-733.
7. Aktas O., Prozorovski T., Smorodchenko A., Savaskan N.E., Lauster R., Kloetzel P.M., Infante-Duarte C., Brocke S., Zipp F. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 2004, 173:5794-5800.
8. Aktas O., Waiczies S., Zipp F. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J. Neuroimmunol. 2007, 184:17-26.
9. Aktas O., Kieseier B., Hartung H.P. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 2010, 33:140-152.
10. Arnon R., Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J. Neural. Transm. 2009, 116:1443-1449.
11. Aulchenko Y.S., Hoppenbrouwers I.A., Ramagopalan S.V., Broer L., Jafari N., Hillert J., Link J., Lundström W., Greiner E., Sadovnick D.A., Goossens D., van Broeckhoven C., del Favero J., Ebers G.C., Oostra B.A., van Duijn C.M., Hintzen R.Q. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat. Genet. 2008, 40:1402-1403.
12. Balatoni B., Storch M.K., Swoboda E.M., Schönborn V., Koziel A., Lambrou G.N., Hiestand P.C., Weissert R., Foster C.A. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull. 2007, 74:307-316.
13. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., Cree B.C., Begovich A.B., Villoslada P., Montalban X., Uccelli A., Savettieri G., Lincoln R.R., DeLoa C., Haines J.L., Pericak-Vance M.A., Compston A., Hauser S.L., Oksenberg J.R. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet. 2006, 15:2813-2824.
14. Baranzini S.E., Bernard C.C., Oksenberg J.R. Modular transcriptional activity characterizes the initiation and progression of autoimmune encephalomyelitis. J. Immunol. 2005, 174:7412-7422.
15. Basso A.S., Frenkel D., Quintana F.J., Costa-Pinto F.A., Petrovic-Stojkovic S., Puckett L., Monsonego A., Bar-Shir A., Engel Y., Gozin M., Weiner H.L. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest. 2008, 118:1532-1543.
16. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7:904-912.
17. Bechtold D.A., Kapoor R., Smith K.J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol. 2004, 55:607-616.
18. Bechtold D.A., Miller S.J., Dawson A.C., Sun Y., Kapoor R., Berry D., Smith K.J. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J. Neurol. 2006, 253:1542-1551.
19. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. 2001, 166:936-944.
20. Ben-Nun A., Wekerle H., Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 1981, 11:195-199.
21. Bettelli E., Baeten D., Jäger A., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 2006, 116:2393-2402.
22. Bieber A., Asakura K., Warrington A., Kaveri S.V., Rodriguez M. Antibody-mediated remyelination: relevance to multiple sclerosis. Mult. Scler. 2000, 6(Suppl. 2):S1-S5.
23. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., McFarland H.F., Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6:1167-1175.
24. Bielekova B., Richert N., Howard T., Packer A.N., Blevins G., Ohayon J., McFarland H.F., Stürzebecher C.S., Martin R. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2009, 15:1206-1214.
25. Bielekova B., Becker B.L. Monoclonal antibodies in MS: mechanisms of action. Neurology 2010, 74(Suppl. 1):S31-S40.
26. Birnbaum G., Cree B., Altafullah I., Zinser M., Reder A.T. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008, 71:1390-1395.
27. Black J.A., Liu S., Carrithers M., Carrithers L.M., Waxman S.G. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann. Neurol. 2007, 62:21-33.
28. Blakemore W.F. Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J. Neurocytol. 1972, 1:413-426.
29. Błaszczyk B., Giełdanowski J., Karakoz I. Experimental allergic encephalomyelitis in chickens. Arch. Immunol. Ther. Exp. (Warsz) 1978, 26:743-746.
30. Blink S.E., Miller S.D. The contribution of gammadelta T cells to the pathogenesis of EAE and MS. Curr. Mol. Med. 2009, 9:15-22.
31. Bourquin C., van der Haar M.E., Anz D., Sandholzer N., Neumaier I., Endres S., Skerra A., Schwab M.E., Linington C. DNA vaccination efficiently induces antibodies to Nogo-A and does not exacerbate experimental autoimmune encephalomyelitis. Eur. J. Pharmacol. 2008, 588:99-105.
32. Boutros T., Croze E., Yong V.W. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem. 1997, 69:939-946.
33. Broberg E.K., Salmi A.A., Hukkanen V. IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis. Neurosci. Lett. 2004, 364:173-178.
34. Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002, 125:1297-1308.
35. Brunmark C., Runström A., Ohlsson L., Sparre B., Brodin T., Aström M., Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 130:163-172.
36. Butti E., Bergami A., Recchia A., Brambilla E., del Carro U., Amadio S., Cattalini A., Esposito M., Stornaiuolo A., Comi G., Pluchino S., Mavilio F., Martino G., Furlan R. IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Ther. 2008, 15:504-1515.
37. Buttmann M., Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev. Neurother. 2008, 8:433-455.
38. CAMMS 223 Trial Investigators, Coles, A.J., Compston, D.A., Selmaj, K.W., Lake, S.L., Moran, S., Margolin, D.H., Norris, K., Tandon, P.K., 2008. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801.
39. Campbell I.L., Stalder A.K., Akwa Y., Pagenstecher A., Asensio V.C. Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation 1998, 5:126-135.
40. Carlson R.P., Baeder W.L., Caccese R.G., Warner L.M., Sehgal S.N. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann. N. Y. Acad. Sci. 1993, 685:86-113.
41. Carlton W.W. Response of mice to the chelating agents sodium diethyldithiocarbamate, alpha-benzoinoxime, and biscyclohexanone oxaldihydrazone. Toxicol. Appl. Pharmacol. 1966, 8:512-521.
42. Casciano D.A., Woodcock J. Empowering microarrays in the regulatory setting. Nat. Biotechnol. 2006, 24:1103.
43. Centonze D., Muzio L., Rossi S., Furlan R., Bernardi G., Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ. 2010, 17:1083-1091.
44. Chao M.J., Barnardo M.C., Lincoln M.R., Ramagopalan S.V., Herrera B.M., Dyment D.A., Montpetit A., Sadovnick A.D., Knight J.C., Ebers G.C. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13069-13074.
45. Charles P., Tait S., Faivre-Sarrailh C., Barbin G., Gunn-Moore F., Denisenko-Nehrbass N., Guennoc A.M., Girault J.A., Brophy P.J., Lubetzki C. Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr. Biol. 2002, 12:217-220.
46. Clifford D.B., de Luca A., Simpson D.M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9:438-446.
47. Cohen B.A., Rieckmann P. Emerging oral therapies for multiple sclerosis. Int. J. Clin. Pract. 2007, 61:1922-1930.
48. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., Tiel-Wieck K., de Vera A., Jin J., Stites T., Wi S., Aradhye S., Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415. TRANSFORMS Study Group.
49. Comabella M., Martin R. Genomics in multiple sclerosis-current state and future directions. J. Neuroimmunol. 2007, 187:1-8.
50. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernández O., Hartung H.-P., Seeldrayers P., Sørensen P.S., Rovaris M., Martinelli V., Hommes O.R. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001, 357:1576-1582. Early Treatment of Multiple Sclerosis Study Group.
51. Comi G., Filippi M., Wolinsky J.S. European/Canadian mutlicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 2001, 49:290-297.
52. Comi G., Pulizzi A., Rovaris M., Abramsky O., Arbizu T., Boiko A., Gold R., Havrdova E., Komoly S., Sharrack B., Filippi M. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092. LAQ/5062 Study Group.
53. Comi G., Martinelli V., Rodegher M., Moiala L., Bajenaru O., Varra A., Elovaara I., Fazekas F., Hartung H.P., Hillert J., King J., Komoly S., Lubetzki C., Montalban X., Myhr K.M., Ravnborg M., Rieckmann P., Wynn D., Young C., Filippi M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) a randomized, double-blind, placebo-controlled trial. Lancet 2009, 374:1503-1511. PreCISe Study Group.
54. Correale J., Farez M., Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs 2008, 22:175-198.
55. Dabbeekeh J.T., Faitar S.L., Dufresne C.P., Cowell J.K. The EVI5 TBC domain provides the GTPase-activating protein motif for RAB11. Oncogene 2007, 26:2804-2808.
56. Dallenga T., Bittner A., Jäger W., Vollmar P., Oertel W.H., Sommer N., Möller J.C., Hemmer B., Stadelmann C., Nessler S. Increased axonal damage in p75NTR-knockout mice after induction of experimental autoimmune encephalomyelitis by adoptive transfer (Abstract). Acta Neuropathol. 2009, 118:436.
57. De Jager P.L., Baecher-Allan C., Maier L.M., Arthur A.T., Ottoboni L., Barcellos L., McCauley J.L., Sawcer S., Goris A., Saarela J., Yelensky R., Price A., Leppa V., Patterson N., de Bakker P.I., Tran D., Aubin C., Pobywajlo S., Rossin E., Hu X., Ashley C.W., Choy E., Rioux J.D., Pericak-Vance M.A., Ivinson A., Booth D.R., Stewart G.J., Palotie A., Peltonen L., Dubois B., Haines J.L., Weiner H.L., Compston A., Hauser S.L., Daly M.J., Reich D., Oksenberg J.R., Hafler D.A. The role of the CD58 locus in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5264-5269.
58. De Jager P.L., Jia X., Wang J., de Bakker P.I., Ottoboni L., Aggarwal N.T., Piccio L., Raychaudhuri S., Tran D., Aubin C., Briskin R., Romano S., International M.S., Genetics Consortium, Baranzini S.E., McCauley J.L., Pericak-Vance M.A., Haines J.L., Gibson R.A., Naeglin Y., Uitdehaag B., Matthews P.M., Kappos L., Polman C., McArdle W.L., Strachan D.P., Evans D., Cross A.H., Daly M.J., Compston A., Sawcer S.J., Weiner H.L., Hauser S.L., Hafler D.A., Oksenberg J.R. Meta-analysis of genome scans and replication identify CD6,IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 2009, 41:776-782.
59. Derfuss T., Parikh K., Velhin S., Braun M., Mathey E., Krumbholz M., Kümpfel T., Moldenhauer A., Rader C., Sonderegger P., Pöllmann W., Tiefenthaller C., Bauer J., Lassmann H., Wekerle H., Karagogeos D., Hohlfeld R., Linington C., Meinl E. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8302-8307.
60. Derfuss T., Linington C., Hohlfeld R., Meinl E. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J. Mol. Med. 2010, (May 6). 10.1007/s00109-010-0632-3.
61. Diem R., Sättler M.B., Merkler D., Demmer I., Maier K., Stadelmann C., Ehrenreich H., Bähr M. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005, 128:375-385.
62. Dimitriadou V., Pang X., Theoharides T.C. Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation. Int. J. Immunopharmacol. 2000, 22:673-684.
63. Dittrich F., Thoenen H., Sendtner M. Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann. Neurol. 1994, 35:151-163.
64. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S17-S24.
65. Duzhak T., Emerson M.R., Chakrabarty A., Alterman M.A., Levine S.M. Analysis of protein induction in the CNS of SJL mice with experimental allergic encephalomyelitis by proteomic screening and immunohistochemistry. Cell. Mol. Biol. (Noisy-le-grand) 2003, 49:723-732.
66. Dziedzic T., Metz I., Dallenga T., König F.B., Müller S., Stadelmann C., Brück W. Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol. 2010, (April 14). 10.1111/j.1750-3639.2010.00401.x.
67. Edan G., Morrissey S.P., Hartung H.P. Use of mitoxantrone to treat multiple sclerosis. Multiple Sclerosis Therapeutics 2007, 457-480. Informa Healthcare, London. J.A. Cohen, R.A. Rudick (Eds.).
68. Einstein E.R., Robertson D.M., DiCaprio J.M., Moore W. The isolation from bovine spinal cord of a homogeneous protein with encephalitogenic activity. J. Neurochem. 1962, 9:353-361.
69. Einstein O., Grigoriadis N., Mizrachi-Kol R., Reinhartz E., Polyzoidou E., Lavon I., Milonas I., Karussis D., Abramsky O., Ben-Hur T. Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp. Neurol. 2006, 198:275-284.
70. Einstein O., Friedman-Levi Y., Grigoriadis N., Ben-Hur T. Transplanted neural precursors enhance host brain-derived myelin regeneration. J. Neurosci. 2009, 29:15694-15702.
71. Elkabes S., Li H. Proteomic strategies in multiple sclerosis and its animal models. Proteomics Clin. Appl. 2007, 1:1393-1405.
72. Encinas J.A., Weiner H.L., Kuchroo V.K. Inheritance of susceptibility to experimental autoimmune encephalomyelitis. J. Neurosci. Res. 1996, 45:655-669.
73. + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008, 111:715-722.
74. Espejo C., Penkowa M., Demestre M., Montalban X., Martínez-Cáceres E.M. Time-course expression of CNS inflammatory, neurodegenerative tissue repair markers and metallothioneins during experimental autoimmune encephalomyelitis. Neuroscience 2005, 132:1135-1349.
75. Evans C.F., Horwitz M.S., Hobbs M.V., Oldstone M.B. Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease. J. Exp. Med. 1996, 184:2371-2384.
76. Eylar E.H., Caccam J., Jackson J.J., Westall F.C., Robinson A.B. Experimental allergic encephalomyelitis: synthesis of disease-inducing site of the basic protein. Science 1970, 168:1220-1223.
77. Faria A.M., Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 2006, 13:143-157.
78. Fathallah-Shaykh H.M. Microarrays: applications and pitfalls. Arch. Neurol. 2005, 62:1669-1672.
79. Fernald G.H., Yeh R.F., Hauser S.L., Oksenberg J.R., Baranzini S.E. Mapping gene activity in complex disorders: integration of expression and genomic scans for multiple sclerosis. J. Neuroimmunol. 2005, 167:157-169.
80. Fitzgerald D.C., Ciric B., Touil T., Harle H., Grammatikopolou J., Das Sarma J., Gran B., Zhang G.X., Rostami A. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179:3268-3275.
81. Foley T.T., Hentosh P., Walters D.E. 2-Chloro-2'-deoxyadenosine: alteration of DNA:TATA element binding protein (TBP) interactions. J. Mol. Model. 2004, 10:32-37.
82. Foster C.A., Mechtcheriakova D., Storch M.K., Balatoni B., Howard L.M., Bornancin F., Wlachos A., Sobanov J., Kinnunen A., Baumruker T. FTY720 rescue therapy in the Dark Agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009, 19:254-266.
83. Fox R.J., Kinkel R.P. High-dose methylprednisolone in the treatment of multiple sclerosis. Multiple Sclerosis Therapeutics 2007, 515-533. Informa Healthcare, London. J.A. Cohen, R.A. Rudick (Eds.).
84. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008, 7:852-858.
85. Franklin R.J., Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 2008, 9:839-855.
86. Freund J., McDermott K. Sensitisation to horse serum by means of adjuvants. Proc. Soc. Exp. Biol. 1942, 49:548-553.
87. Freund J., Stern E.R., Pisani T.M. Isoallergic encephalomyelitis and radiculitis in guinea pigs after one injection of brain and mycobacteria in water-in-oil emulsion. J. Immunol. 1947, 57:179-194.
88. + T cells in multiple sclerosis. Nat. Med. 2008, 14:1227-1235.
89. + T cells in multiple sclerosis. Ann. Neurol. 2009, 66:132-141.
90. Furlan R., Pluchino S., Martino G. Gene therapy-mediated modulation of immune processes in the central nervous system. Curr. Pharm. Des. 2003, 9:2002-2008.
91. Furtado G.C., Piña B., Tacke F., Gaupp S., van Rooijen N., Moran T.M., Randolph G.J., Ransohoff R.M., Chensue S.W., Raine C.S., Lira S.A. A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells. J. Immunol. 2006, 177:6871-6879.
92. Garay L., Gonzalez Deniselle M.C., Gierman L., Meyer M., Lima A., Roig P., De Nicola A.F. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neuroimmunomodulation 2008, 15:76-83.
93. Gauthier S.A., Weiner H.L. Use of cyclophosphamide and other immunosuppressants to treat multiple sclerosis. Multiple Sclerosis Therapeutics. 2007, 481-498. Informa Healthcare, London. J.A. Cohen, R.A. Rudick (Eds.).
94. Gavériaux-Ruff C., Kieffer B.L. Conditional gene targeting in the mouse nervous system: Insights into brain function and diseases. Pharmacol. Ther. 2007, 113:619-634.
95. Genain C.P., Nguyen M.H., Letvin N.L., Pearl R., Davis R.L., Adelman M., Lees M.B., Linington C., Hauser S.L. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 1995, 96:2966-2974.
96. Giovannoni G., Comi G., Cook S., Rammohan K., Rieckmann P., Soelberg Sorensen P., Vermersch P., Chang P., Hamlett A., Musch B., Greenberg S.J. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:416-426. CLARITY Study Group.
97. Goertsches R., Zettl U.K. MS therapy research applying genome-wide RNA profiling of peripheral blood. Int. MS J. 2007, 14:98-107.
98. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
99. Gold R., Lühder F. Interleukin-17-extended features of a key player in multiple sclerosis. Am. J. Pathol. 2008, 172:8-10.
100. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, the MS Council for Clinical Practice Guidelines.
101. Goodkin D.E., Rudick R.A., VanderBrug Medendorp S., Daughtry M.M., Schwetz K.M., Fischer J., Van Dyke C. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 1995, 37:30-40.
102. Gould K.E., Stepaniak J.A., Swanborg R.H. Variable susceptibility of Lewis rats to experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1994, 54:145-146.
103. Goverman J., Woods A., Larson L., Weiner L.P., Hood L., Zaller D.M. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993, 72:551-560.
104. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
105. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., Caillier S.J., Ban M., Goris A., Barcellos L.F., Lincoln R., McCauley J.L., Sawcer S.J., Compston D.A., Dubois B., Hauser S.L., Garcia-Blanco M.A., Pericak-Vance M.A., Haines J.L. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 2007, 39:1083-1091. Multiple Sclerosis Genetics Group.
106. Haak S., Croxford A.L., Kreymborg K., Heppner F.L., Pouly S., Becher B., Waisman A. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 2009, 119:61-69.
107. Haase C.G., Guggenmos J., Brehm U., Andersson M., Olsson T., Reindl M., Schneidewind J.M., Zettl U.K., Heidenreich F., Berger T., Wekerle H., Hohlfeld R., Linington C. The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J. Neuroimmunol. 2001, 114:220-225.
108. Hafler, J.P., Maier, L.M., Cooper, J.D., Plagnol, V., Hinks, A., Simmonds, M.J., Stevens, H.E., Walker, N.M., Healy, B., Howson, J.M., Maisuria, M., Duley, S., Coleman, G., Gough, S.C., International Multiple Sclerosis Genetics Consortium (IMSGC), Worthington, J., Kuchroo, V.K., Wicker, L.S., Todd, J.A., 2009. [226CD] Gly307Ser association with multiple autoimmune diseases. Genes Immun. 10, 5-10.
109. Han M.H., Hwang S.I., Roy D.B., Lundgren D.H., Price J.V., Ousman S.S., Fernald G.H., Gerlitz B., Robinson W.H., Baranzini S.E., Grinnell B.W., Raine C.S., Sobel R.A., Han D.K., Steinman L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451:1076-1081.
110. Hartung H.P., Gonsette R., König N., Kwiecinski H., Guseo A., Morrissey S.P., Krapf H., Zwingers T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025. Mitoxantrone in Multiple Sclerosis Study Group (MIMS).
111. Hartung H.P., Kieseier B.C., Hemmer B. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J. Neurol. 2005, 252(Suppl. 5):v30-v37.
112. Hartung H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 2009, 8:28-31.
113. Hartung H.P., Warnke C., Hohlfeld R., Kieseier B.C. Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy (German). Nervenarzt 2009, 80:1143-1144. 1146-1148, 1150-1153.
114. Hartung H.P., Aktas O., Kieseier B., Comi G. Development of oral cladribine for the treatment of multiple sclerosis. J. Neurol. 2010, 257:207-211.
115. Hassen G.W., Feliberti J., Kesner L., Stracher A., Mokhtarian F. Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. Brain Res. 2008, 1236:206-215.
116. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688. HERMES Trial Group.
117. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C.H. Rituximab in patients with primary progressive muoltiple sclerosis: results of a randomized, double-blind, placebo-controlled multicentre trial. Ann. Neurol. 2009, 66:460-471. OLYMPUS Trial Group.
118. Hedstrom K.L., Xu X., Ogawa Y., Frischknecht R., Seidenbecher C.I., Shrager P., Rasband M.N. Neurofascin assembles a specialized extracellular matrix at the axon initial segment. J. Cell Biol. 2007, 178:875-886.
119. Hemmer B., Hartung H.P. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?. Ann. Neurol. 2007, 62:314-326.
120. Hendriks J.J., Alblas J., van der Pol S.M., van Tol E.A., Dijkstra C.D., de Vries H.E. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J. Exp. Med. 2004, 200:1667-1672.
121. Herder V., Hansmann F., Stangel M., Baumgärtner W., Beineke A. Cuprizone ameliorates spinal cord inflammation in a viral model of multiple sclerosis. Acta Neuropathol. 2009, 118:443-444. (abstract).
122. Herrero-Herranz E., Pardo L.A., Gold R., Linker R.A. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol. Dis. 2008, 30:162-173.
123. Herz J., Zipp F., Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp. Neurol. 2009, (December 1). 10.1016/j.expneurol.2009.11.019.
124. Hofstetter H.H., Grau C., Buttmann M., Forsthuber T.G., Gaupp S., Toyka K.V., Gold R. The PLP-specific T-cell population promoted by pertussis toxin is characterized by high frequencies of IL-17-producing cells. Cytokine 2007, 40:35-43.
125. Hofstetter H.H., Gold R., Hartung H.P. Th17 cells in MS and experimental autoimmune encephalomyelitis. Int. MS J. 2009, 16:12-18.
126. Hohlfeld R., Meinl E., Dornmair K. B- and T-cell responses in multiple sclerosis: novel approaches offer new insights. J. Neurol. Sci. 2008, 274:5-8.
127. Hoppenbrouwers I.A., Aulchenko Y.S., Ebers G.C., Ramagopalan S.V., Oostra B.A., van Duijn C.M., Hintzen R.Q. EVI5 is a risk gene for multiple sclerosis. Genes Immun. 2008, 9:334-337.
128. Hoppenbrouwers I.A., Aulchenko Y.S., Janssens A.C., Ramagopalan S.V., Broer L., Kayser M., Ebers G.C., Oostra B.A., van Duijn C.M., Hintzen R.Q. Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. J. Hum. Genet. 2009, 54:676-680.
129. Hövelmeyer N., Hao Z., Kranidioti K., Kassiotis G., Buch T., Frommer F., von Hoch L., Kramer D., Minichiello L., Kollias G., Lassmann H., Waisman A. Apoptosis of oligodendrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J. Immunol. 2005, 175:5875-5884.
130. + Tc17 cells with reduced cytotoxic activity. Eur. J. Immunol. 2009, 39:1716-1725.
131. Hünig T. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv. Immunol. 2007, 95:111-148.
132. Huppert J., Closhen D., Croxford A., White R., Kulig P., Pietrowski E., Bechmann I., Becher B., Luhmann H.J., Waisman A., Kuhlmann C.R. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 2010, 24:1023-1034.
133. + T cells in a model for multiple sclerosis. J. Exp. Med. 2001, 194:669-676.
134. Ibrahim S.M., Mix E., Böttcher T., Koczan D., Gold R., Rolfs A., Thiesen H.J. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 2001, 124:1927-1938.
135. Ibrahim S.M., Gold R. Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis?. Curr. Opin. Neurol. 2005, 18:231-235.
136. Imitola J., Chitnis T., Khoury S.J. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 2005, 106:163-177.
137. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., Hauser S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862. IMSGC International Multiple Sclerosis Genetics Consortium.
138. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000, 343:898-904.
139. Jäger A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009, 183:7169-7177.
140. Jagodic M., Kornek B., Weissert R., Lassmann H., Olsson T., Dahlman I. Congenic mapping confirms a locus on rat chromosome 10 conferring strong protection against myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. Immunogenetics 2001, 53:410-415.
141. Jagodic M., Olsson T. Combined-cross analysis of genome-wide linkage scans for experimental autoimmune encephalomyelitis in rat. Genomics 2006, 88:737-744.
142. Jelinsky S.A., Miyashiro J.S., Saraf K.A., Tunkey C., Reddy P., Newcombe J., Oestreicher J.L., Brown E., Trepicchio W.L., Leonard J.P., Marusic S. Exploiting genotypic differences to identify genes important for EAE development. J. Neurol. Sci. 2005, 239:81-93.
143. Johnson B.A., Wang J., Taylor E.M., Caillier S.J., Herbert J., Khan O.A., Cross A.H., de Jager P.L., Gourraud P.A., Cree B.C., Hauser S.L., Oksenberg J.R. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun. 2010, 11:343-350.
144. Jones J.L., Coles A.J. Campath-1H treatment of multiple sclerosis. Neurodegener. Dis. 2008, 5:27-31.
145. Jones R.E., Moes N., Zwickey H., Cunningham C.L., Gregory W.L., Oken B. Treatment of experimental autoimmune encephalomyelitis with alpha lipoic acid and associative conditioning. Brain Behav. Immun. 2008, 22:538-543.
146. Jørgensen S.H., Storm N., Jensen P.E., Laursen H., Sørensen P.S. IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp. Brain Res. 2007, 178:462-469.
147. Kabat E.A., Wolf A., Bezer A.E. The rapid production of acute disseminated encephalomyelitis in rhesus monkeys by injection of heterologous and homologous brain tissue with adjuvants. J. Exp. Med. 1947, 85:117-130.
148. Kanter J.L., Narayana S., Ho P.P., Catz I., Warren K.G., Sobel R.A., Steinman L., Robinson W.H. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 2006, 12:138-143.
149. Kappos L., Patzold U., Dommasch D., Poser S., Haas J., Krauseneck P., Malin J.P., Fierz W., Graffenried B.U., Gugerli U.S. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis-results of the German multicenter study. Ann. Neurol. 1988, 23:56-63.
150. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 2000, 6:1176-1182.
151. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., Montalban X., Barkhof F., Bauer L., Jakobs P., Pohl C., Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
152. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn A.A., Karlsson G., Radue E.W. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 355:1124-1140. FTY720 D2201 Study Group.
153. Kappos L., Lindberg R.L.P. Interferons in relapsing-remitting multiple sclerosis. Multiple Sclerosis Therapeutics 2007, 373-392. Informa Healthcare, London. J.A. Cohen, R.A. Rudick (Eds.).
154. Kappos L., Freedman M.S., Polman C.H., Edan G., Hartung H.P., Miller D.H., Montalbán X., Barkhof F., Radü E.W., Bauer L., Dahms S., Lanius V., Pohl C., Sandbrink R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397. BENEFIT Study Group.
155. Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Yang M., Eraksoy M., Meluzinova E., Rektor I., Dawson K.T., Sandrock A.W., O'Neill G.N. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372:1463-1472. BG-12 Phase IIb Study Investigators.
156. Karpus W.J., Reynolds N., Behanna H.A., Van Eldik L.J., Watterson D.M. Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. J. Neuroimmunol. 2008, 203:73-78.
157. + regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 2007, 9:144-157.
158. Kerschensteiner M., Meinl E., Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Neuroscience 2009, 158:1122-1132.
159. Khare M., Mangalam A., Rodriguez M., David C.S. HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. J. Neuroimmunol. 2005, 169:1-12.
160. Kieseier B.C., Hartung H.P. Current disease-modifying therapies in multiple sclerosis. Sem. Neurol. 2003, 23:133-146.
161. Kieseier B.C., Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 2007, 21:483-502.
162. Kipp M., Clarner T., Dang J., Copray S., Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 2009, 118:723-736.
163. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 2005, 353:369-374.
164. Kobayashi N., Kiptoo P., Kobayashi H., Ridwan R., Brocke S., Siahaan T.J. Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin. Immunol. 2008, 129:69-79.
165. + T cells specific for an astrocyte protein, S100 beta. J. Neural. Transm. Suppl. 1997, 49:43-51.
166. Koritschoner R., Schweinburg F. Klinsche und experimentelle Beobachtungen über Lähmungen nach Wutschutzimpfung. Z. Immunitäts-Forsch. 1925, 42:217-283.
167. H17 cells. Nature 2007, 448:484-487.
168. Krapf H., Morrissey S.P., Zenker O., Zwingers T., Gonsette R., Hartung H.P. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005, 65:690-695. MIMS Study Group.
169. Krishnamoorthy G., Holz A., Wekerle H. Experimental models of spontaneous autoimmune disease in the central nervous system. J. Mol. Med. 2007, 85:1161-1173.
170. Krishnamoorthy G., Saxena A., Mars L.T., Domingues H.S., Mentele R., Ben-Nun A., Lassmann H., Dornmair K., Kurschus F.C., Liblau R.S., Wekerle H. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat. Med. 2009, 15:626-632.
171. Laatsch R.H., Kies M.W., Gordon S., Alvord E.C. The encephalomyelitic activity of myelin isolated by ultracentrifugation. J. Exp. Med. 1962, 115:77-88.
172. Lafaille J.J., Nagashima K., Katsuki M., Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994, 78:399-408.
173. Lange F., Bajtner E., Rintisch C., Nandakumar K.S., Sack U., Holmdahl R. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann. Rheum. Dis. 2005, 64:599-5605.
174. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 2005, 353:375-381.
175. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
176. Lavi E. Histopathology in coronavirus-induced demyelination. Experimental Models of Multiple Sclerosis 2005, 711-716. Springer, New York. E. Lavi, C.S. Constantinescu (Eds.).
177. Experimental Models of Multiple Sclerosis 2005, Springer, New York. E. Lavi, C.S. Constantinescu (Eds.).
178. Lebar R., Lubetzki C., Vincent C., Lombrail P., Boutry J.M. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin. Exp. Immunol. 1986, 66:423-434.
179. Lees J.R., Iwakura Y., Russell J.H. Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines. J. Immunol. 2008, 180:8066-8072.
180. Lennon V.A., Wilks A.V., Carnegie P.R. Immunologic properties of the main encephalitogenic peptide from the basic protein of human myelin. J. Immunol. 1970, 105:1223-1230.
181. Lenz D.C., Lu L., Conant S.B., Wolf N.A., Gérard H.C., Whittum-Hudson J.A., Hudson A.P., Swanborg R.H. A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats. J. Immunol. 2001, 167:1803-1808.
182. Lindsey J.W. EAE: history, clinical signs, and disease course. Experimental Models of Multiple Sclerosis 2005, 1-9. Springer, New York. E. Lavi, C.S. Constantinescu (Eds.).
183. Lindå H., von Heijne A., Major E.O., Ryschkewitsch C., Berg J., Olsson T., Martin C. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 2009, 361:1081-1087.
184. Link H. The cytokine storm in multiple sclerosis. Mult. Scler. 1998, 4:12-15.
185. Linker R.A., Sendtner M., Gold R. Mechanisms of axonal degeneration in EAE-lessons from CNTF and MHC I knockout mice. J. Neurol. Sci. 2005, 233:167-172.
186. Linker R.A., Kruse N., Israel S., Wei T., Seubert S., Hombach A., Holtmann B., Lühder F., Ransohoff R.M., Sendtner M., Gold R. Leukemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: a new role for neurotrophic cytokines in neuroinflammation. J. Immunol. 2008, 180:2204-2213.
187. Linker R.A., Weller C., Lühder F., Mohr A., Schmidt J., Knauth M., Metselaar J.M., Gold R. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp. Neurol. 2008, 211:397-406.
188. Linker R.A., Kieseier B.C., Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol. Sci. 2008, 29:558-565.
189. Linker R.A., Brechlin P., Jesse S., Steinacker P., Lee D.H., Asif A.R., Jahn O., Tumani H., Gold R., Otto M. Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. PLoS One 2009, 4:e7624. (1-9).
190. Linker R.A., Gold R., Lühder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit. Rev. Immunol. 2009, 29:43-68.
191. Lipton M.M., Freund J. Encephalomyelitis in the rat following intracutaneous injection of central nervous system tissue with adjuvant. Proc. Soc. Exp. Biol. Med. 1952, 81:260-261.
192. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
193. Liu T., Donahue K.C., Hu J., Kurnellas M.P., Grant J.E., Li H., Elkabes S. Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. J. Proteome Res. 2007, 6:2565-2575.
194. Liu X., Leung S., Wang C., Tan Z., Wang J., Guo T.B., Fang L., Zhao Y., Wan B., Qin X., Lu L., Li R., Pan H., Song M., Liu A., Hong J., Lu H., Zhang J.Z. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat. Med. 2010, 16:191-197.
195. Lo A.C., Saab C.Y., Black J.A., Waxman S.G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol. 2003, 90:3566-3571.
196. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
197. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., Racke M.K. Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease. J. Immunol. 2004, 172:5790-5798.
198. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
199. Lühder F., Reichardt H.M. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit. Rev. Immunol. 2009, 29:255-273.
200. Luo J., Ho P., Steinman L., Wyss-Coray T. Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease. J. Neuroinflammation 2008, 5:6. (1-6).
201. Lutterotti A., Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008, 7:538-547.
202. Makar T.K., Trisler D., Bever C.T., Goolsby J.E., Sura K.T., Balasubramanian S., Sultana S., Patel N., Ford D., Singh I.S., Gupta A., Valenzuela R.M., Dhib-Jalbut S. Stem cell based delivery of IFN-β reduces relapses in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2008, 196:67-81.
203. Makar T.K., Trisler D., Sura K.T., Sultana S., Patel N., Bever C.T. Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. J. Neurol. Sci. 2008, 270:70-76.
204. Mangalam A.K., Rajagopalan G., Taneja V., David C.S. HLA class II transgenic mice mimic human inflammatory diseases. Adv. Immunol. 2008, 97:65-147.
205. Mangano K., Nicoletti A., Patti F., Donia M., Malaguarnera L., Signorelli S., Magro G., Muzio V., Greco B., Zaratin P., Meroni P., Zappia M., Nicoletti F. Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clin. Exp. Immunol. 2010, 159:159-168.
206. Marrie R.A., Cohen J.A. Interferons in secondary progressive multiple sclerosis. Multiple Sclerosis Therapeutics 2007, 393-407. Informa Healthcare, London. J.A. Cohen, R.A. Rudick (Eds.).
207. Martin Mdel P., Monson N.L. Potential role of humoral immunity in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Front. Biosci. 2007, 12:2735-2749.
208. Martino G., Pluchino S. Neural stem cells: guardians of the brain. Nat. Cell Biol. 2007, 9:1031-1034.
209. Määttä J.A., Käldman M.S., Sakoda S., Salmi A.A., Hinkkanen A.E. Encephalitogenicity of myelin-associated oligodendrocytic basic protein and 2',3'-cyclic nucleotide 3'-phosphodiesterase for BALB/c and SJL mice. Immunology 1998, 95:383-388.
210. Matà S., Lolli F., Söderström M., Pinto F., Link H. Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult. Scler. 1999, 5:379-388.
211. Matejuk A., Hopke C., Dwyer J., Subramanian S., Jones R.E., Bourdette D.N., Vandenbark A.A., Offner H. CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2003, 73:667-678.
212. Mathey E.K., Derfuss T., Storch M.K., Williams K.R., Hales K., Woolley D.R., Al-Hayani A., Davies S.N., Rasband M.N., Olsson T., Moldenhauer A., Velhin S., Hohlfeld R., Meinl E., Linington C. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 2007, 204:2363-2372.
213. Mayo S., Quinn A. Altered susceptibility to EAE in congenic NOD mice: Altered processing of the encephalitogenic MOG35-55 peptide by NOR/LtJ mice. Clin. Immunol. 2007, 122:91-100.
214. Mazón Peláez I., Vogler S., Strauss U., Wernhoff P., Pahnke J., Brockmann G., Moch H., Thiesen H.J., Rolfs A., Ibrahim S.M. Identification of quantitative trait loci controlling cortical motor evoked potentials in experimental autoimmune encephalomyelitis: correlation with incidence, onset and severity of disease. Hum. Mol. Genet. 2005, 14:1977-1989.
215. McCombe P.A., Harness J., Pender M.P. Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. J. Neuroimmunol. 1999, 97:60-69.
216. McKenzie B.S., Kastelein R.A., Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006, 27:17-23.
217. McLaughlin K.A., Wucherpfennig K.W. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv. Immunol. 2008, 98:121-149.
218. Melzer N., Meuth S.G., Torres-Salazar D., Bittner S., Zozulya A.L., Weidenfeller C., Kotsiari A., Stangel M., Fahlke C., Wiendl H. A β-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One 2008, 3:e3149. (1-12).
219. Mendel I., Natarajan K., Ben-Nun A., Shevach E.M. A novel protective model against experimental allergic encephalomyelitis in mice expressing a transgenic TCR-specific for myelin oligodendrocyte glycoprotein. J. Neuroimmunol. 2004, 149:10-21.
220. Merkler D., Ernsting T., Kerschensteiner M., Brück W., Stadelmann C. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 2006, 129:1972-1983.
221. Mero I.L., Lorentzen A.R., Ban M., Smestad C., Celius E.G., Aarseth J.H., Myhr K.M., Link J., Hillert J., Olsson T., Kockum I., Masterman T., Oturai A.B., Søndergaard H.B., Sellebjerg F., Saarela J., Kemppinen A., Elovaara I., Spurkland A., Dudbridge F., Lie B.A., Harbo H.F. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur. J. Hum. Genet. 2010, 18:502-504.
222. + channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J. Biol. Chem. 2008, 283:14559-14570.
223. Mi S., Hu B., Hahm K., Luo Y., Kam Hui E.S., Yuan Q., Wong W.M., Wang L., Su H., Chu T.H., Guo J., Zhang W., So K.F., Pepinsky B., Shao Z., Graff C., Garber E., Jung V., Wu E.X., Wu W. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233.
224. Mi S., Miller R.H., Tang W., Lee X., Hu B., Wu W., Zhang Y., Shields C.B., Zhang Y., Miklasz S., Shea D., Mason J., Franklin R.J., Ji B., Shao Z., Chédotal A., Bernard F., Roulois A., Xu J., Jung V., Pepinsky B. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann. Neurol. 2009, 65:304-315.
225. Miron V.E., Schubart A., Antel J.P. Central nervous system-directed effects of FTY720 (fingolimod). J. Neurol. Sci. 2008, 274:13-17.
226. Miron V.E., Ludwin S.K., Darlington P.J., Jarjour A.A., Soliven B., Kennedy T.E., Antel J.P. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol. 2010, 176:2682-2694.
227. Mirowska-Guzel D. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis. Immunopharmacol. Immunotoxicol. 2009, 31:32-38.
228. - T cells in CSF and blood of patients with multiple sclerosis and tension headache. Scand. J. Immunol. 1990, 31:493-501.
229. Mix E., Pahnke J., Ibrahim S.M. Gene-expression profiling of experimental autoimmune encephalomyelitis. Neurochem. Res. 2002, 27:1157-1163.
230. Mix E., Ibrahim S., Pahnke J., Koczan D., Sina C., Böttcher T., Thiesen H.J., Rolfs A. Gene-expression profiling of the early stages of MOG-induced EAE proves EAE-resistance as an active process. J. Neuroimmunol. 2004, 151:158-170.
231. Mix E., Ibrahim S.M., Pahnke J., Glass A., Mazón-Peláez I., Lemcke S., Koczan D., Gimsa U., Bansemer S., Scheel T., Karopka T., Böttcher T., Müller J., Dazert E., Antipova V., Hoffrogge R., Wree A., Zschiesche M., Strauss U., Kundt G., Warzok R., Gierl L., Rolfs A. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. J. Autoimmun. 2006, 27:251-265.
232. Mix E., Goertsches R., Zettl U.K. Immunology and neurology. J. Neurol. 2007, 254(Suppl. 2):II2-II7.
233. Mix E., Meyer-Rienecker H., Zettl U.K. Animal models of multiple sclerosis for the development and validation of novel therapies. Potentials and limitations. J. Neurol. 2008, 255(Suppl. 6):7-14.
234. Mörtl M., Sonderegger P., Diederichs K., Welte W. The crystal structure of the ligand-binding module of human TAG-1 suggests a new mode of homophilic interaction. Protein Sci. 2007, 16:2174-2183.
235. Morgan I.M. Allergic encephalomyelitis in monkeys in response to injection of normal monkey nervous tissue. J. Exp. Med. 1947, 85:131-140.
236. Morrissey S.P., Stodal H., Zettl U., Simonis C., Jung S., Kiefer R., Lassmann H., Hartung H.P., Haase A., Toyka K.V. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain 1996, 119:239-248.
237. Munoz J.J., Bernard C.C., Mackay I.R. Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. Cell. Immunol. 1984, 83:92-100.
238. Nakano K., Higashi T., Hashimoto K., Takagi R., Tanaka Y., Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 2008, 373:286-291.
239. Nath N., Giri S., Prasad R., Salem M.L., Singh A.K., Singh I. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol. 2005, 175:566-574.
240. Neuhaus O., Wiendl H., Kieseier B.C., Archelos J.J., Hemmer B., Stüve O., Hartung H.P. Multiple sclerosis: mitoxantrone promotes differential effects in immunocompetent cells in vitro. J. Neuroimmunol. 2005, 168:128-137.
241. Neuhaus O., Kieseier B.C., Hartung H.P. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol. Ther. 2006, 109:198-209.
242. Neuhaus O., Kieseier B.C., Hartung H.P. Mitoxantrone in multiple sclerosis. Adv. Neurol. 2006, 98:293-302.
243. Neuhaus O., Kieseier B.C., Hartung H.P. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 2007, 4:654-660.
244. Noseworthy J.H., O'Brien P., Erickson B.J., Lee D., Sneve D., Ebers G.C., Rice G.P., Auty A., Hader W.J., Kirk A., Duquette P., Carter J., Francis G., Metz L., Shuster E. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998, 51:1342-1352.
245. Noseworthy J.H., Wolinsky J.S., Lublin F.D., Whitaker J.N., Linde A., Gjorstrup P., Sullivan H.C. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000, 54:1726-1733.
246. Nowak E.C., Weaver C.T., Turner H., Begum-Haque S., Becher B., Schreiner B., Coyle A.J., Kasper L.H., Noelle R.J. IL-9 as a mediator of Th17-driven inflammatory disease. J. Exp. Med. 2009, 206:1653-1660.
247. O'Connor P.W., Li D., Freedman M.S., Bar-Or A., Rice G.P., Confavreux C., Paty D.W., Stewart J.A., Scheyer R. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006, 66:894-900. Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
248. Ohler B., Graf K., Bragg R., Lemons T., Coe R., Genain C., Israelachvili J., Husted C. Role of lipid interactions in autoimmune demyelination. Biochim. Biophys. Acta 2004, 1688:10-17.
249. Olitzky P.K., Yager R.H. Experimental disseminated encephalomyelitis in white mice. J. Exp. Med. 1949, 90:213-224.
250. Olsson T., Dahlman I., Wallström E., Weissert R., Piehl F. Genetics of rat neuroinflammation. J. Neuroimmunol. 2000, 107:191-200.
251. Ousman S.S., Tomooka B.H., van Noort J.M., Wawrousek E.F., O'Connor K.C., Hafler D.A., Sobel R.A., Robinson W.H., Steinman L. Protective and therapeutic role for αB-crystallin in autoimmune demyelination. Nature 2007, 448:474-479.
252. Owens T., Wekerle H., Antel J. Genetic models for CNS inflammation. Nat. Med. 2001, 7:161-166.
253. Ozenci V., Kouwenhoven M., Link H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult. Scler. 2002, 8:396-404.
254. Paintlia A.S., Paintlia M.K., Singh A.K., Stanislaus R., Gilg A.G., Barbosa E., Singh I. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J. Neurosci. Res. 2004, 77:63-81.
255. Paintlia A.S., Paintlia M.K., Singh I., Singh A.K. Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am. J. Pathol. 2006, 169:1012-1025.
256. Paintlia A.S., Paintlia M.K., Singh I., Singh A.K. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp. Neurol. 2008, 214:168-180.
257. Paintlia A.S., Paintlia M.K., Singh I., Skoff R.B., Singh A.K. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2009, 57:182-193.
258. Papadopoulos D., Rundle J., Patel R., Marshall I., Stretton J., Eaton R., Richardson J.C., Gonzalez M.I., Philpott K.L., Reynolds R. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J. Neurosci. Res. 2010, 88:346-359.
259. Pasteur L., Illo J. Pasteur and rabies: an interview of 1882. Med. Hist. 1996, 40:373-377.
260. Paterson P.Y. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J. Exp. Med. 1960, 111:119-136.
261. Paul C., Bolton C. Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone or cyclosporin A. Int. J. Immunopharmacol. 1995, 17:497-503.
262. Pedemonte E., Benvenuto F., Casazza S., Mancardi G., Oksenberg J.R., Uccelli A., Baranzini S.E. The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics 2007, 8:65. (1-14).
263. Pender M.P., Csurhes P.A., Wolfe N.P., Hooper K.D., Good M.F., McCombe P.A., Greer J.M. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J. Clin. Neurosci. 2003, 10:63-66.
264. Pedersen L.B., Nashold F.E., Spach K.M., Hayes C.E. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J. Neurosci. Res. 2007, 85:2480-2490.
265. Pernet V., Joly S., Christ F., Dimou L., Schwab M.E. Nogo-A and myelin-associated glycoprotein differently regulate oligodendrocyte maturation and myelin formation. J. Neurosci. 2008, 28:7435-7444.
266. Platten M., Ho P.P., Youssef S., Fontoura P., Garren H., Hur E.M., Gupta R., Lee L.Y., Kidd B.A., Robinson W.H., Sobel R.A., Selley M.L., Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005, 310:850-855.
267. Plioplys A.V., Massimini N. Alpha/beta interferon is a neuronal growth factor. Neuroimmunomodulation 1995, 2:31-35.
268. Pluchino S., Martino G. The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis. J. Neurol. Sci. 2008, 265:105-110.
269. Podbielska M., Hogan E.L. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?. Mult. Scler. 2009, 15:1011-1029.
270. Pöllinger B., Krishnamoorthy G., Berer K., Lassmann H., Bösl M.R., Dunn R., Domingues H.S., Holz A., Kurschus F.C., Wekerle H. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 2009, 206:1303-1316.
271. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovanonni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910. AFFIRM Investigators.
272. Pomeroy I.M., Matthews P.M., Frank J.A., Jordan E.K., Esiri M.M. Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 2005, 128:2713-2721.
273. Pomeroy I.M., Jordan E.K., Frank J.A., Matthews P.M., Esiri M.M. Diffuse cortical atrophy in a marmoset model of multiple sclerosis. Neurosci. Lett. 2008, 437:121-124.
274. Prinz M., Schmidt H., Mildner A., Knobeloch K.P., Hanisch U.K., Raasch J., Merkler D., Detje C., Gutcher I., Mages J., Lang R., Martin R., Gold R., Becher B., Brück W., Kalinke U. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.
275. Qin J., Goswami R., Balabanov R., Dawson G. Oxidized phosphatidylcholine is marker for euroinflammation in multiple sclerosis brain. J. Neurosci. Res. 2007, 85:977-984.
276. H17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
277. Quintana F.J., Farez M.F., Viglietta V., Iglesias A.H., Merbl Y., Izquierdo G., Lucas M., Basso A.S., Khoury S.J., Lucchinetti C.F., Cohen I.R., Weiner H.L. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18889-18894.
278. Racke M.K., Lovett-Racke A.E., Karandikar N.J. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S25-S30.
279. H-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
280. Rice G.P., Hartung H.P., Calabresi P. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005, 64:1336-1342.
281. Ridge S.C., Sloboda A.E., McReynolds R.A., Levine S., Oronsky A.L., Kerwar S.S. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin. Immunol. Immunopathol. 1985, 35:35-42.
282. Rieckmann P., Weber F., Günther A., Poser S. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis. Neurology 1996, 47:604.
283. Rieckmann P., Toyka K.V., Bassetti C., Beer K., Beer S., Buettner U., Chofflon M., Götschi-Fuchs M., Hess K., Kappos L., Kesselring J., Goebels N., Ludin H.P., Mattle H., Schluep M., Vaney C., Baumhackl U., Berger T., Deisenhammer F., Fazekas F., Freimüller M., Kollegger H., Kristoferitsch W., Lassmann H., Markut H., Strasser-Fuchs S., Vass K., Altenkirch H., Bamborschke S., Baum K., Benecke R., Brück W., Dommasch D., Elias W.G., Gass A., Gehlen W., Haas J., Haferkamp G., Hanefeld F., Hartung H.P., Heesen C., Heidenreich F., Heitmann R., Hemmer B., Hense T., Hohlfeld R., Janzen R.W., Japp G., Jung S., Jügelt E., Koehler J., Kölmel W., König N., Lowitzsch K., Manegold U., Melms A., Mertin J., Oschmann P., Petereit H.F., Pette M., Pöhlau D., Pohl D., Poser S., Sailer M., Schmidt S., Schock G., Schulz M., Schwarz S., Seidel D., Sommer N., Stangel M., Stark E., Steinbrecher A., Tumani H., Voltz R., Weber F., Weinrich W., Weissert R., Wiendl H., Wiethölter H., Wildemann U., Zettl U.K., Zipp F., Zschenderlein R., Izquierdo G., Kirjazovas A., Packauskas L., Miller D., Koncan Vracko B., Millers A., Orologas A., Panellus M., Sindic C.J., Bratic M., Svraka A., Vella N.R., Stelmasiak Z., Selmaj K., Bartosik-Psujik H., Mitosek-Szewczyk K., Belniak E., Mochecka A., Bayas A., Chan A., Flachenecker P., Gold R., Kallmann B., Leussink V., Mäurer M., Ruprecht K., Stoll G., Weilbach F.X. Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J. Neurol. 2004, 251:1329-1339. Multiple Sclerosis Therapy Consensus Group.
284. Rivers T.M., Sprunt D.H., Berry G.P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 1933, 58:39-53.
285. Robinson W.H., Fontoura P., Lee B.J., de Vegvar H.E., Tom J., Pedotti R., DiGennaro C.D., Mitchell D.J., Fong D., Ho P.P., Ruiz P.J., Maverakis E., Stevens D.B., Bernard C.C., Martin R., Kuchroo V.K., van Noort J.M., Genain C.P., Amor S., Olsson T., Utz P.J., Garren H., Steinman L. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 2003, 21:1033-1039.
286. Rose J.W., Burns J.B., Bjorklund J., Klein J., Watt H.E., Carlson N.G. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007, 69:785-789.
287. Rose J.W., Foley J., Carlson N. Monoclonal antibody treatments for multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2008, 8:419-426.
288. Rosenthale M.E., Gluckman M.I. Immunopharmacologic activity of 1-aminocyclopentane-1-carboxylic acid. Experientia 1968, 24:1229-1230.
289. Rubio J.P., Stankovich J., Field J., Tubridy N., Marriott M., Chapman C., Bahlo M., Perera D., Johnson L.J., Tait B.D., Varney M.D., Speed T.P., Taylor B.V., Foote S.J., Butzkueven H., Kilpatrick T.J. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun. 2008, 9:624-630.
290. Rudick R.A., Mi S., Sandrock A.W. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin. Biol. Ther. 2008, 8:1561-1570.
291. Runström A., Leanderson T., Ohlsson L., Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J. Neuroimmunol. 2006, 173:69-78.
292. Ruuls S.R., de Labie M.C., Weber K.S., Botman C.A., Groenestein R.J., Dijkstra C.D., Olsson T., van der Meide P.H. The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J. Immunol. 1996, 157:5721-5757.
293. Sättler M.B., Merkler D., Maier K., Stadelmann C., Ehrenreich H., Bähr M., Diem R. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ. 2004, 11(Suppl. 2):S181-S192.
294. Sarrias M.R., Farnós M., Mota R., Sánchez-Barbero F., Ibáñez A., Gimferrer I., Vera J., Fenutría R., Casals C., Yélamos J., Lozano F. CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11724-11729.
295. Schilling S., Goelz S., Linker R., Lühder F., Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 2006, 145:101-107.
296. Schmidt J., Gold R., Schönrock L., Zettl U.K., Hartung H.P., Toyka K.V. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000, 123:1431-1441.
297. Schreiner B., Heppner F.L., Becher B. Modeling multiple sclerosis in laboratory animals. Semin. Immunopathol. 2009, 31:479-495.
298. Scolding N. Stem cell therapy in patients with multiple sclerosis. Mult. Scler. 2006, 12:677-678.
299. Seehusen F., Baumgärtner W. Axonal pathology and loss precede demyelination and accompany chronic lesions in a spontaneously occurring animal model of multiple sclerosis. Brain Pathol. 2010, 20:551-559.
300. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008, 7:796-804. Ustekinumab MS Investigators.
301. Serrano-Fernández P., Ibrahim S.M., Zettl U.K., Thiesen H.J., Gödde R., Epplen J.T., Möller S. Intergenomic consensus in multifactorial inheritance loci: the case of multiple sclerosis. Genes Immun. 2004, 5:615-620.
302. Shamshiev A., Donda A., Carena I., Mori L., Kappos L., De Libero G. Self glycolipids as T-cell autoantigens. Eur. J. Immunol. 1999, 29:1667-1675.
303. Shimoda Y., Watanabe K. Contactins: emerging key roles in the development and function of the nervous system. Cell Adh. Migr. 2009, 3:64-70.
304. Siffrin V., Vogt J., Radbruch H., Nitsch R., Zipp F. Multiple sclerosis-candidate mechanisms underlying CNS atrophy. Trends Neurosci. 2010, 33:202-210.
305. Singh N.P., Hegde V.L., Hofseth L.J., Nagarkatti M., Nagarkatti P. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 2007, 72:1508-1521.
306. Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J., Beutler E. Development of cladribine treatment in multiple sclerosis. Mult. Scler. 1996, 1:343-347.
307. Skripuletz T., Bussmann J.H., Gudi V., Koutsoudaki P.N., Pul R., Moharregh-Khiabani D., Lindner M., Stangel M. Cerebellar cortical demyelination in the murine cuprizone model. Brain Pathol. 2010, 20:301-312.
308. Smith T., Groom A., Zhu B., Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 2000, 6:62-66.
309. Sobottka B., Harrer M.D., Ziegler U., Fischer K., Wiendl H., Hünig T., Becher B., Goebels N. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am. J. Pathol. 2009, 175:1160-1166.
310. Sriram S., Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 2005, 58:939-945.
311. Stanislaus R., Pahan K., Singh A.K., Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 1999, 269:71-74.
312. Steinman L. Some misconceptions about understanding autoimmunity through experiments with knockouts. J. Exp. Med. 1997, 185:2039-2041.
313. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
314. H2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13:139-145.
315. Steinman L. Mixed results with modulation of Th17 cells in human autoimmune disease. Nat. Immunol. 2010, 11:41-44.
316. + channel-blocking alkoxypsoralens inhibit the immune response of encephalitogenic T line cells and lymphocytes from Lewis rats challenged for experimental autoimmune encephalomyelitis. Immunopharmacology 2000, 48:51-63.
317. Stuart G., Krikorian K.S. The neuro-paralytic accidents of anti-rabies treatment. Ann. Trop. Med. 1928, 22:327-377.
318. Stüve O., Bennett J.L. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 2007, 13:79-95.
319. Tajouri L., Fernandez F., Griffiths L.R. Gene expression studies in multiple sclerosis. Curr. Genomics 2007, 8:181-189.
320. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1:242-248.
321. Teuscher C., Doerge R.W., Fillmore P.D., Blankenhorn E.P. eae36, a locus on mouse chromosome 4, controls susceptibility to experimental allergic encephalomyelitis in older mice and mice immunized in the winter. Genetics 2006, 172:1147-1153.
322. Theiler M. Spontaneous encephalomyelitis of mice-a new virus disease. Science 1934, 80:122.
323. Tischner D., Weishaupt A., van den Brandt J., Müller N., Beyersdorf N., Ip C.W., Toyka K.V., Hünig T., Gold R., Kerkau T., Reichardt H.M. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 2006, 129:2635-2647.
324. Torkildsen O., Brunborg L.A., Myhr K.M., Bø L. The cuprizone model for demyelination. Acta Neurol. Scand. Suppl. 2008, 188:72-76.
325. Trebst C., Stangel M. Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis. Curr. Pharm. Des. 2006, 12:241-249.
326. Tuohy V.K., Lu Z.J., Sobel R.A., Laursen R.A., Lees M.B. A synthetic peptide from myelin proteolipid protein induces experimental allergic encephalomyelitis. J. Immunol. 1988, 141:1126-1130.
327. Ure D.R., Rodriguez M. Histopathology in the Theiler's virus model of demyelination. Experimental Models of Multiple Sclerosis 2005, 579-592. Springer, New York. E. Lavi, C.S. Constantinescu (Eds.).
328. van der Meide P.H., de Labie M.C., Ruuls S.R., Groenestein R.J., Botman C.A., Olsson T., Dijkstra C.D. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J. Neuroimmunol. 1998, 84:14-23.
329. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., Woody J.N., Hartung H.P., Polman C.H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
330. Vollmar P., Nessler S., Kalluri S.R., Hartung H.P., Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int. J. Neuropsychopharmacol. 2008, 16:1-12.
331. Vollmer T., Stewart T., Baxter N. Mitoxantrone and cytotoxic drugs mechanisms of action. Neurology 2010, 74(Suppl. 1):S41-S46.
332. Waiczies S., Bendix I., Zipp F. Geranylgeranylation but not GTP-loading of Rho GTPases determines T cell function. Sci. Signal 2008, 1:pt3. (1-3).
333. Wang J., Wang G., Sun B., Li H., Mu L., Wang Q., Li G., Shi L., Jin L., Kostulas N. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J. Autoimmun. 2008, 30:222-229.
334. Weber F., Polak T., Günther A., Kubuschok B., Janovskaja J., Bitsch A., Poser S., Rieckmann P. Synergistic immunomodulatory effects of '1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann. Neurol. 1998, 44:27-34.
335. Wegner C., Stadelmann C., Brück W. Therapeutic treatment with Laquinimod reduces inflammation, demyelination and axonal damage in experimental autoimmune encephalomyelitis. Acta Neuropathol. 2009, 118:464. (abstract).
336. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
337. Weishaupt A., Kuhlmann T., Schönrock L.M., Toyka K.V., Brück W., Gold R. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol. 2002, 104:385-390.
338. Wekerle H., Kojima K., Lannes-Vieira J., Lassmann H., Linington C. Animal models. Ann. Neurol. 1994, 36(Suppl.):S47-S53.
339. Wenning W., Haghikia A., Laubenberger J., Clifford D.B., Behrens P.F., Chan A., Gold R. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med. 2009, 361:1075-1080.
340. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002, 16:183-200.
341. Wolf A., Kabat E.A., Bezer A.E. The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease. J. Neuropath. Exp. Neurol. 1947, 6:333-357.
342. Wright B.R., Waarington A.E., Rodriguez M. Cellular mechanisms of central nervous system repair by natural autoreactive antibodies. Arch. Neurol. 2009, 66:1456-1459.
343. Wulff H., Castle N.A., Pardo L.A. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov. 2009, 8:982-1001.
344. Wynn D., Kaufman M., Montalban X., Vollmer T., Simon J., Elkins J., O'Neill G., Neyer L., Sheridan J., Wang C., Fong A., Rose J.W. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blin, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010, 9:381-390. CHOICE Investigators.
345. Yang J.S., Xu L.Y., Xiao B.G., Hedlund G., Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 2004, 156:3-9.
346. Yang Y., Liu Y., Wei P., Peng H., Winger R., Hussain R.Z., Ben L.H., Cravens P.D., Gocke A.R., Puttaparthi K., Racke M.K., McTigue D.M., Lovett-Racke A.E. Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann. Neurol. 2010, 67:498-507.
347. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992, 356:63-66.
348. + T cells. Cell. Mol. Immunol. 2006, 3:189-195.
349. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., Barkhof F., Radue E.W., Jäger H.R., Clifford D.B. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2006, 354:924-933.
350. Youssef S., Stüve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
351. Yuan R., Maeda Y., Li W., Lu W., Cook S., Dowling P. Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One 2008, 3:e1924. (1-18).
352. Yudkin P.L., Ellison G.W., Ghezzi A., Goodkin D.E., Hughes R.A., McPherson K., Mertin J., Milanese C. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991, 338:1051-1055.
353. Zettl U.K., Mix E., Zielasek J., Stangel M., Hartung H.P., Gold R. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell. Immunol. 1997, 178:1-8.
354. Zeyda M., Poglitsch M., Geyeregger R., Smolen J.S., Zlabinger G.J., Hörl W.H., Waldhäusl W., Stulnig T.M., Säemann M.D. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005, 52:2730-2739.
355. Zhu J., Mix E., Winblad B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev. 2001, 7:387-398.
356. Ziemssen T., Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun. Rev. 2005, 4:460-467.
357. Zorzella S.F., Seger J., Martins D.R., Pelizon A.C., Sartori A. Resistance to experimental autoimmune encephalomyelitis development in Lewis rats from a conventional animal facility. Mem. Inst. Oswaldo Cruz 2007, 102:931-936.
358. Zozulya A.L., Wiendl H. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Hum. Immunol. 2008, 69:780-797.